Suppr超能文献

阻塞性气道疾病患者使用不同β1-肾上腺素能受体选择性的β受体阻滞剂的长期临床影响比较:一项基于意大利人群的队列研究。

Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study.

作者信息

Sessa Maurizio, Mascolo Annamaria, Scavone Cristina, Perone Ilaria, Di Giorgio Annalisa, Tari Michele, Fucile Annamaria, De Angelis Antonella, Rasmussen Daniel Bech, Jensen Magnus Thorsten, Kragholm Kristian, Rossi Francesco, Capuano Annalisa, Sportiello Liberata

机构信息

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.

出版信息

Front Pharmacol. 2018 Oct 25;9:1212. doi: 10.3389/fphar.2018.01212. eCollection 2018.

Abstract

Long-term clinical implications of beta-blockade in obstructive airway diseases remains controversial. We investigated if within the first 5 years of treatment patients with heart failure and obstructive airway diseases using non β1-adrenoreceptor selective beta-blockers have an increased risk of being hospitalized for all-causes, heart failure, and chronic obstructive pulmonary disease (COPD) when compared to patient using selective beta-blockers. Carvedilol users were propensity matched 1:1 for co-treatments, age, gender, and year of inclusion in the cohort with metoprolol/bisoprolol/nebivolol users. Cox proportional hazard regression model was used to compare all causes, COPD, and heart failure hospitalization or the beta-blocker discontinuation between cohorts. For statistically significant associations, we computed the rate difference and the attributable risk. Overall, 11,844 patients out of the 51,214 (23.1%) were exposed to carvedilol and 39,370 (76.9%) to metoprolol/bisoprolol/nebivolol. Carvedilol users had a higher hazard for heart failure hospitalization (HR 1.29; 95% Confidence Interval [CI] 1.18-1.40) with 106 (95%CI 76-134; -value < 0.001) additional cases of heart failure hospitalization per 10000 person-years if compared to metoprolol/bisoprolol/nebivolol users. In all, 26.8% (95%CI 22.5-30.9%; -value < 0.001) of heart failure hospitalizations in the study population could be attributed to being exposed to carvedilol. Carvedilol users had a higher hazard (HR 1.06; 95%CI 1.02-1.10) of discontinuing the pharmacological treatment with 131 (95%CI 62-201; -value < 0.001) additional cases of beta-blocker discontinuation per 10000 person-years metoprolol/bisoprolol/nebivolol users. In all, 6.5% (95%CI 3.9-9.0%; -value < 0.001) of beta-blocker discontinuation could be attributed to being exposed to carvedilol. On long-term follow-up period, carvedilol was associated with a higher risk of heart failure hospitalization and discontinuation if compared to metoprolol/bisoprolol/nebivolol users among patients with heart failure and obstructive airway diseases.

摘要

β受体阻滞剂在阻塞性气道疾病中的长期临床影响仍存在争议。我们调查了在治疗的前5年内,与使用选择性β受体阻滞剂的患者相比,使用非β1肾上腺素能受体选择性β受体阻滞剂的心力衰竭和阻塞性气道疾病患者因各种原因、心力衰竭和慢性阻塞性肺疾病(COPD)住院的风险是否增加。将使用卡维地洛的患者与使用美托洛尔/比索洛尔/奈必洛尔的患者在联合治疗、年龄、性别和纳入队列的年份方面进行1:1倾向匹配。使用Cox比例风险回归模型比较各队列之间因各种原因、COPD和心力衰竭住院或β受体阻滞剂停药的情况。对于具有统计学意义的关联,我们计算了率差和归因风险。总体而言,51214名患者中有11844名(23.1%)使用了卡维地洛,39370名(76.9%)使用了美托洛尔/比索洛尔/奈必洛尔。与使用美托洛尔/比索洛尔/奈必洛尔的患者相比,使用卡维地洛的患者因心力衰竭住院的风险更高(风险比[HR] 1.29;95%置信区间[CI] 1.18 - 1.40),每10000人年有106例(95%CI 76 - 134;P值<0.001)额外的心力衰竭住院病例。在研究人群中,所有心力衰竭住院病例的26.8%(95%CI 22.5 - 30.9%;P值<0.001)可归因于使用卡维地洛。使用卡维地洛的患者停药的风险更高(HR 1.06;95%CI 1.02 - 1.10),每10000人年有131例(95%CI 62 - 201;P值<0.001)额外的β受体阻滞剂停药病例,与使用美托洛尔/比索洛尔/奈必洛尔 的患者相比。在所有β受体阻滞剂停药病例中,6.5%(95%CI 3.9 - 9.0%;P值<0.001)可归因于使用卡维地洛。在长期随访期间,与使用美托洛尔/比索洛尔/奈必洛尔的患者相比,在心力衰竭和阻塞性气道疾病患者中,卡维地洛与更高的心力衰竭住院风险和停药风险相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff2/6232895/ddde5a37107b/fphar-09-01212-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验